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Background
The safety and efficacy of Monomeric Carbamylated
Allergoid in injections have been previously reported in
adult patients. The aim of this case-series was to explore
its safety in a paediatric populations. Monomeric Carba-
mylated Allergoids are chemically modified extracts
characterized by hypoallergenic activity due to allergen
lysines substitution and preserved structural conforma-
tion and size of the native allergen.
Methods
A total of 37 children (21 males, 16 females), mean age
8.06 years, were treated with Monomeric Allergoid in
injections for house dust mite respiratory allergy (persis-
tent rhinitis with/without mild asthma), and were followed
up for a period of at least 12 months. After a build-up
phase of 4 weeks (0.1 /0.2 /0.3 /0.5 mL per week), the
treatment continued with monthly injection of 0.5mL. A
standard questionnaire was used to collect data on local
and systemic adverse reactions (ARs). The severity was
graded as low (no need for treatment or dose adjustment),
moderate (interference with activities/need for drugs/SCIT
discontinuation), and severe (hospitalization/emergency
care). A parental satisfaction on the clinical outcome
(based on symptoms and drug consumption) was also col-
lected (excellent, good, low, very low).
Results
Only one patient interrupted the treatment after 6 months
because he suffered from recurrent febrile upper respiratory
infections. There were no serious ARs. Only at first admin-
istration we observed: 2 pain at the arm, 1 episode of head-
ache, 2 of diffuse itching, 1 case of mild dyspnoea with no
treatment interruptions, no hospitalizations and no dose-
correlation. Parents’ satisfaction was judged excellent by
51%, good by 43.5%, low by 5.5% of the patients’ parents.
Conclusions
The safety of immunotherapy with Monomeric Aller-
goid through an injective route appears confirmed also
in paediatric patients. High patients’ acceptance and
satisfaction have been observed.
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